Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056662 | 0.87 | TDP1 (0.52) | POLBTDP1NPC1SMN1; SMN2MAPT | |
| SCHEMBL8960223 | 0.84 | LMNA (0.44) | POLBTDP1NPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4212542 | 0.84 | GAA (0.43) | POLBALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL26626501 | 0.81 | L3MBTL1 (0.50) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL1741676 | 0.81 | L3MBTL1 (0.50) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL12520029 | 0.80 | NPC1 (0.49) | POLBNPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12253600 | 0.79 | POLB (0.46) | POLBTDP1NPC1MAPTRAB9A | |
| SCHEMBL678436 | 0.78 | TDP1 (0.56) | POLBTDP1NPC1SMN1; SMN2MAPT | |
| SCHEMBL20315921 | 0.78 | MEN1 (0.61) | POLBTDP1NPC1ALDH1A1MAPT | |
| SCHEMBL20315922 | 0.78 | RAB9A (0.49) | TDP1NPC1SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153617-B2 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090105262-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | ALLACCEM, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090074833-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION | ALLACCEM, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2001079410-A1 | PROCESS OF CLEANING AND/OR DISINFECTING A HARD SURFACE WITH A COMPOSITION COMPRISING A BIGUANIDE ANTIMICROBIAL AGENT | THE PROCTER & GAMBLE COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105262-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | PAICS, KRTCAP2, OSTC | POLB 1083/4885TDP1 3457/4885NPC1 1844/4885 |
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | OTC, SLC16A8, SLC16A7 | POLB 890/4885TDP1 2355/4885NPC1 657/4885 |
| US-20090074833-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION | BMP2, BMP1, BMP6 | POLB 1797/4885TDP1 4081/4885NPC1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.